

## **Additional Files**

**Additional file 1-Table S1:** Binding of epitopes of IvAgNP from Influenza virus against MHC II alleles

**Additional file 2-Table S2:** Binding affinity of predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 from IvAgNP to MHC alleles

**Additional file 3-Table S3:** Accession numbers of antigenic Ag85B sequences of *Mycobacterium* pathogenic strains found in protein database

**Additional file 4-Figure S1:** Multiple alignment of protein sequences of IvAgNP from Influenza virus

**Additional file 5-Table S4:** Hydrogen Bonds and binding statistics of epitope 181-QQFIYAGSLSALLDP-195 from Ag85B with MHC II complexes

**Additional file 6-Figure S2:** Docking of predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 from IvAgNP with HLA-DRB1\*0101 (A), DRB1\*0901 (B), DRB1\*0404 (C) and DRB1\*0701 (D)

**Additional file 7-Table S5:** Hydrogen Bonds and binding statistics of predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 from IvAgNP with MHC II complexes

**Additional file 8-Table S6:** Hydrogen Bonds and binding statistics of epitope 181-QQFIYAGSLSALLDP-195 from Ag85B with MHC I complexes

**Additional file 9-Figure S3:** Docking of control epitope 380-ELRSRYWAIRTRSG-393 from IvAgNP with HLA-B8 (A) and B27 (B)

**Additional file 10-Table S7:** Hydrogen Bonds and binding statistics of control epitope 380-ELRSRYWAIRTRSG-393 from IvAgNP with MHC I complexes

**Additional file 11-Figure S4:** Docking of predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 from IvAgNP with HLA-A2 (A), A3 (B), B27 (C), B39 (D) and B58 (E)

**Additional file 12-Table S8:** Hydrogen Bonds and binding statistics of predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 from IvAgNP with MHC I complexes

**Additional file 13-Figure S5:** Multiple alignments of amino acid sequences of HLA-A and HLA-B series

**Additional file 1-Table S1:** Binding of epitopes of IvAgNP from Influenza virus against MHC II molecules<sup>a</sup>

MHC II molecule	Strongest epitope				No of strong binding epitopes	No of weak binding epitopes
	Start position	Full peptide (15 mer)	Core peptide (9 mer)	Affinity (nM)		
<b>HLA-DRB1*0101</b>	<b>301</b>	<b>IDPFRLQLNSQVYSL</b>	<b>FRLQLNSQV</b>	<b>3.4</b>	<b>98</b>	<b>212</b>
HLA-DRB1*0301	106	RELILYDKKEIRRIW	ILYDKKEIR	7.6	7	59
HLA-DRB1*0401	441	RTEIIRMMESARPEDDP	IRMMESARP	12	13	139
HLA-DRB1*0404	302	FRLQLNSQVYSLIVGID	FRLQLNSQV	7.4	28	139
HLA-DRB1*0405	299	PFRLQLNSQVY	FRLQLNSQV	18.4	13	109
HLA-DRB1*0701	339	EDLRVLSFIKGTKVLTE	LSFIKGTKV	4	39	112
HLA-DRB1*0901	442	IIRMMESARPEVD	IRMMESARP	27.6	10	110
HLA-DRB1*1101	190	VMELVRMIKRGINDRT	LVRMIKRGV	8.6	36	117
HLA-DRB1*1302	360	RGVQIASNENMETMT	VQIASNENM	41.1	2	57
HLA-DRB1*1501	378	LELRSRYWAIRTRS	TLELRSRYW	26.8	8	103
HLA-DRB3*0101	484	EGSYFFGDNAEEYDN	FFGDNAEEY	16.1	3	46
HLA-DRB4*0101	440	MRTEIIRMMESARPE	IRMMESARP	15.6	9	131
HLA-DRB5*0101	225	ILKGFQTAQAQKAMM	GKGFQTAQK	8.8	52	114
HLA-DPA1*0103	250	NAEFEDLTFLARSAL	FEDLTFLAR	7.8	6	52
-DPB1*0401						
HLA-DPA1*0103	247	NPGNAEFEDLTFLAR	FEDLTFLAR	13.8	17	83
-DPB1*0201						
HLA-DPA1*0201	250	NAEFEDLTFLARSAL	FEDLTFLAR	14.5	19	105
-DPB1*0101						
HLA-DPA1*0301	247	NPGNAEFEDLTFLAR	FEDLTFLAR	24.7	12	39
-DPB1*0402						
HLA-DQA1*0101-	334	HSAAFEDLRVLSFIK	FEDLRVLSF	11.8	35	76
DQB1*0501						
HLA-DQA1*0102-	332	ACHSAAFEDLRVLSF	HSAAFEDLR	14	5	25
DQB1*0602						
HLA-DQA1*0102-	439	DMRTEIIRMMESARP	TEIIRMMES	11.2	42	138
DQB1*0602						
HLA-DQA1*0501-	483	NEGSYFFGDNAEEYD	FFGDNAEEY	13	3	23
DQB1*0201						
HLA-DQA1*0501-	170	STLPRRSGAAGAAVK	SGAAGAAVK	7.8	56	126
DQB1*0301						

<sup>a</sup>NetMHCII 2.2 server was used for predication of epitopes from IvAgNP that showed strong binding affinity with 22 MHC II molecules. Affinity, below 50 nM is considered strong immunogenicity. The strongest epitope bound to HLA-DRB1\*0101 MHC II molecule is shaded.

**Additional file 2-Table S2:** Binding affinity of predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 from IvAgNP to MHC alleles <sup>a</sup>

MHC II Alleles	Promiscuous peptide sequence		Affinity (nM)
	Full peptide (15 mer)	Core peptide (9 mer)	
HLA-DRB1*0101	IDPFRLQLNSQVYSL	FRLQLNSQV	3.4
HLA-DRB1*0404	IDPFRLQLNSQVYSL	FRLQLNSQV	7.8
HLA-DRB1*0405	IDPFRLQLNSQVYSL	FRLQLNSQV	21.1
HLA-DRB1*0701	IDPFRLQLNSQVYSL	FRLQLNSQV	32.6
HLA-DRB1*0901	IDPFRLQLNSQVYSL	FRLQLNSQV	39.4

<sup>a</sup>MHC allele was predicted by NetMHCII 2.2 servers. Binding affinity below 50 nM is considered high immunogenicity.

**Additional file 3-Table S3:** Accession numbers of all antigenic Ag85-B sequences of *Mycobacterium* pathogenic strains found in protein database

<i>Mycobacterium</i> pathogenic strain	Accession number	Number of identical sequences	Number of amino acid	Accession number of Identical sequences
<i>M. Tuberculosis_2</i> CDC1551	NP_336393.1	2	374	NP_336393.1, AAK46207.1
<i>M. Bovis_1</i> BCG str. Pasteur 1173P2	YP_978013.1	10	325	YP_978013.1, YP_005171366.1, AET19183.1, CCC64491.1, ADD50055.1, YP_002644961.1, BAH26193.1, A1KJU9.1, CAL71910.1, CAA44268.1
<i>M. Tuberculosis_4</i> SUMu003	ZP_07422952.2	12	322	ZP_07422952.2, YP_005913165.1, YP_005909553.1, BAL65871.1, AEJ50558.1, AEJ46932.1, EGB28751.1, ZP_074402622, ZP_07436007.2, EFP38634.1, EFP30851.1, EFP19521.1
<i>M. Tuberculosis_5</i> H37Ra	ZP_02552646.1	25	310	ZP_02552646.1, GAA45592.1, ZP_07815649.1, EFP54785.1, EFP51110.1, EFP47207.1, EFP43274.1, EFP34332.1, EFP27102.1, EFP23309.1, EFP16040.1, EFO74877.1, ZP_07493616.1, ZP_07489096.1, ZP_07484878.1, ZP_07480643.1, ZP_07444836.1, ZP_07431632.1, ZP_07427317.1, ZP_07418226.1, ZP_07414444.1, ZP_06960553.1, ZP_06952228.1, ZP_06802485.1, ZP_05141345.1
<i>M. bovis_2</i>	AAA25359.1	9	323	AAA25359.1, AAQ77588.1, AAN20429.1, AAN19158.1, AAE80437.1, AAE55762.1, AAE40111.1, AAE36056.1, AAE31577.1
<i>M. Tuberculosis_3</i>	1F0P A	1	285	1F0P A
<i>M. Intracellulare_3</i>	BAA03243.1	1	264	BAA03243.1
<i>M. Intracellulare_1</i> ATCC 13950	YP_005338175.1	6	315	YP_005338175.1, YP_005348339.1, YP_005343334.1, AFC54018.1, AFC49013.1, AFC43854.1
<i>M. Tuberculosis_6</i>	1F0N_A	1	285	1F0N_A
<i>M. kansasii</i> ATCC 12478	ZP_04749192.1	5	325	ZP_04749192.1, AAR68430.1, AAE27820.1, P21160.1, CAA37868.1
<i>M. avium_1</i>	Q06947.1	3	330	AAM58787.1, Q06947.1, CAA45032.1
<i>M. Tuberculosis_7</i>	AAO62005.1	1	325	AAO62005.1
<i>M. intracellulare_2</i> ATCC 13950	BAA03981.1	1	330	BAA03981.1
<i>M. avium_2</i> subsp. Paratuberculosis	AAM21939.1	1	330	AAM21939.1
<i>M. Tuberculosis_1</i> H37Rv	NP_216402.1	72	325	P0C5B9.1, YP_006515286.1, YP_005916959.1, YP_004745346.1, YP_004723581.1, YP_006473577.1, YP_005308170.1, YP_005923115.1, YP_005100587.1, ZP_07012790.1, ZP_06521415.1, ZP_06517371.1, ZP_06509845.1, ZP_06454795.1, ZP_06450191.1, ZP_06513358.1, ZP_06505060.1, ZP_06437244.1, ZP_06433108.1, ZP_04980753.1, ZP_04925390.1, YP_003032071.1, YP_001283215.1, YP_001287851.1, A5U3Q3.1, P0C2T2.1, NP_855570.1, AFE13119.1, CCE37368.1, AEN00338.1, EGE50422.1, EFD43577.1, EFD17659.1, EFD13523.1, EFD73559.1, EFD47366.1, AEB04248.1, EFI30469.1, EFD77569.1, EFD61996.1, EFD53698.1, EFD58483.1, ACT25176.1, ABQ73653.1, EBA42266.1, AFN49815.1, ABR06249.1, EAY60132.1, AFM49500.1, CCC26978.1, CCC44233.1, ADS25363.1, AAC44294.1, ADD50054.1, ADF19013.1, ABY17327.1, ABY08008.1, CAD94621.1, CAB10044.1, ACC93938.1, CAA44269.1, ABE22073.1, AAQ77586.1, AAN19156.1, AAN20427.1, AAM58786.1, AAE80435.1, AAE55760.1, AAE40109.1, AAE36054.1, AAE31575.1



<sup>a</sup>The control epitope 380-ELRSRYWAIRTRSG-393 and the predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 is shown in the box. The epitope sequences from Influenza A virus is underlined. Non-identical epitope sequences are shaded and the amino acid residues for which the epitope varies are bold, italic and underlined


**Additional file 5-Table S4:** Hydrogen Bonds and binding statistics of epitope 181-QQFIYAGSLSALLDP-195 with MHC II complexes<sup>a</sup>

Epitope-MHC II complex	No. of H-bonds	Binding energy (kcal/mol)	Receptor residues in MHC I	Ligand residues in epitope	Interacting atoms	H-bond distance (Å)
Epitope-HLA-DRB1*0101	9	-181.93	W61	Q1	H-O	2.55
			Q64	Q1	H-O	1.85
			Q70	Y5	H-O	2.43
			R71	Q2	H-O	1.84
			R71	Q2	H-O	1.97
			Y78	L9	H-O	1.65
			N82	S10	H-O	2.11
			Q64	Q1	O-H	2.25
			T77	Y5	O-H	2.56
Epitope-HLA-DRA	6	-204.17	N69	L13	H-O	2.41
			N69	P15	H-O	2.45
			N69	L13	H-O	2.18
			E11	S10	O-H	2.38
			F48	Q2	O-H	2.48
			F48	Q2	O-H	2.64
Epitope-HLA-DRB1*0404	9	-162.42	H13	Q1	H-O	2.64
			Y60	L13	H-O	2.76
			D28	Q1	O-H	2.38
			D28	Q1	O-H	2.65
			Q64	D14	O-H	2.78
			D66	S10	O-H	2.38
			D66	S8	O-H	2.36
			Q70	Y5	O-H	2.30
			T77	Q2	O-H	2.14
Epitope-HLA-DRB1*0701	8	-179.42	C15	P15	H-O	2.14
			S60	Q1	H-O	2.62
			W61	I4	H-O	2.46
			R71	L9	H-O	2.38
			Q74	D14	H-O	1.92
			N82	D14	H-O	2.19
			N82	L13	H-O	2.14
			Q64	Q1	O-H	2.76
Epitope-HLA-DRB1*0901	6	-178.35	Y26	D14	H-O	2.22
			Y26	D14	H-O	2.70
			R71	L13	H-O	2.32
			R71	L13	H-O	2.53
			T77	P15	H-O	2.59
			Y32	I4	O-H	2.40
Epitope-HLA-DPB1*0101	5	-159.39	N62	S8	H-O	2.66
			N62	S8	H-O	2.01
			Y9	S10	O-H	2.50
			G58	S8	O-H	2.28
			A64	Q2	O-H	2.55
Epitope-HLA-DQB1*0301	9	-202.60	Y37	L13	H-O	2.38
			Y37	D14	H-O	2.34
			W61	A11	H-O	2.79
			Q64	S10	H-O	2.47
			R70	L9	H-O	2.52
			N82	Q1	H-O	2.70
			Q64	S10	O-H	2.13
			T77	Q1	O-H	2.20
			N82	Q1	O-H	2.10

<sup>a</sup>Hydrogen bonding distance and binding energy were analyzed in Molsoft ICM-pro 3.5 computer program. Fifteen amino acid residues in the epitope (181-QQFIYAGSLSALLDP-195) have been numbered 1-15.



**Additional file 6-Figure S2:** Docking of predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 from IvAgNP with HLA-DRB1\*0101 (A), DRB1\*0901 (B), DRB1\*0404 (C) and DRB1\*0701 (D)<sup>a</sup>



<sup>a</sup>MHC II structures are shown in grey ribbon and the amino acid residues involved in the H-bonding interaction are shown as red sticks and labeled red. The epitope is shown as in green ribbon and the amino acid residues involved in the H-bonding network are shown as yellow sticks and labeled black. MHC II binding pocket(s) are shown as electrostatic sphere. H-bonds are displayed as blue spheres and the H-bonding distances are labeled blue. H-bonding interaction between the amino acid residues of the epitope and those of the MHC II are detailed in additional file 7- Table S5.

**Additional file 7-Table S5:** Hydrogen Bonds and binding statistics of predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 from IvAgNP with MHC II complexes<sup>a</sup>

Epitope-MHC II complex	No. of H-bonds	Binding energy (kcal/mol)	Receptor residues in MHC I	Ligand residues in epitope	Interacting atoms	H-bond distance (Å)
Epitope-HLA-DRB1*0101	9	-194.87	T77	P3	H-O	2.15
			R71	R5	O-H	2.85
			Q70	R5	H-O	1.23
			R71	P3	H-O	1.54
			R71	L7	O-H	1.91
			Y60	S14	H-O	2.55
			L28	S10	O-H	2.41
			L28	S10	O-H	2.05
			L28	V12	O-H	2.16
Epitope-HLA-DRB1*0901	9	-211.17	N82	D2	H-O	1.41
			N82	F4	O-H	1.45
			H28	F4	H-O	2.18
			Y26	R5	O-H	2.48
			F24	R5	H-O	2.88
			W61	Q8	O-H	2.64
			S60	S10	H-O	2.14
			R56	N9	H-O	2.13
			R56	Q11	H-O	2.12
Epitope-HLA-DRB1*0404	7	-189.62	T77	I1	H-O	2.04
			R71	R5	H-O	2.16
			Q70	L7	O-H	2.28
			G20	S10	O-H	1.65
			Y60	Y13	H-O	1.88
			D28	R5	O-H	2.08
			D28	R5	O-H	2.06
Epitope-HLA-DRB1*0701	8	-185.42	Y83	I1	H-O	2.04
			N33	P3	O-H	2.12
			N33	R5	H-O	2.36
			D76	S10	O-H	2.08
			Q74	Y13	H-O	1.95
			Q74	Y13	H-O	2.26
			D76	Q11	O-H	2.35
			N33	L6	O-H	2.14

<sup>a</sup>Hydrogen bonding distance and binding energy were analyzed in Molsoft ICM-pro 3.5 computer program. Fifteen amino acid residues in the epitope (301-IDPFRLQLNSQVYSL-315) have been numbered 1-15.




**Additional file 8-Table S6:** Hydrogen Bonds and binding statistics of epitope 181-QQFIYAGSLSALLDP-195 from Ag85B with MHC I complexes <sup>a</sup>

Epitope-MHC I complex	No. of H-bonds	Binding energy (kcal/mol)	Receptor residues in MHC I	Ligand residues in epitope	Interacting atoms	H-bond distance (Å)
Epitope (183-FIYAGSLSA-191)-HLA-A2	8	-162.01	H70	Y3	H-O	2.79
			Y116	S8	H-O	2.66
			W147	A9	H-O	2.58
			Q155	S6	H-O	1.84
			Y159	F1	H-O	1.92
			E63	F1	O-H	2.70
			Y99	Y3	O-H	2.11
			Q155	S6	O-H	2.22
Epitope (184-IYAGSLSAL-192)-HLA-A24	7	-185.45	K66	Y2	H-O	2.18
			N77	S7	H-O	1.75
			Y84	L9	H-O	2.71
			T143	L9	H-O	2.55
			W147	A8	H-O	1.49
			E63	I1	O-H	2.70
			N77	L9	O-H	1.80
Epitope (181-QQFIYAGS L-189)-HLA-B27	11	-193.62	Y59	L9	H-O	2.61
			R62	G7	H-O	2.07
			R62	S8	H-O	1.95
			Y99	Q1	H-O	1.83
			T143	Q2	H-O	2.01
			W147	S8	H-O	2.50
			Y159	L9	H-O	2.35
			Y171	Q1	H-O	2.14
			E63	L9	O-H	2.05
			D77	Q2	O-H	1.88
			D116	Q1	O-H	2.41
Epitope (181-QQFIYAGS L-189)-HLA-B44	11	-200.13	Y9	Q2	H-O	1.81
			R62	Q1	H-O	1.73
			Y74	Y5	H-O	2.31
			Y99	Q2	H-O	2.39
			T143	S8	H-O	1.72
			Y9	Q2	O-H	1.73
			E63	Q1	O-H	1.90
			E63	Q2	O-H	1.89
			N77	L9	O-H	2.52
			D116	Y5	O-H	2.66
			S167	Q1	O-H	2.67
Epitope (184-IYAGSLSAL-192)-HLA-B39	7	175.42	Y84	L9	H-O	2.28
			K146	L9	H-O	2.44
			W147	S7	H-O	2.79
			W147	A8	H-O	1.82
			S77	L9	O-H	1.97
			Y99	Y2	O-H	2.24
			E152	S5	O-H	2.31

<sup>a</sup>Hydrogen bonding distance and binding energy were analyzed in Molsoft ICM-pro 3.5 computer program. Nine amino acid residues in each 9-mer of epitope have been numbered 1-9.

**Additional file 9-Figure S3:** Docking of control epitope 380-ELRSRYWAIRTRSG-393 from IvAgNP with HLA-B8 (A) and B27 (B)<sup>a</sup>



<sup>a</sup>MHC I structures are shown in grey ribbon and the amino acid residues involved in the H-bonding interaction are shown as red sticks and labeled red. The epitope is shown as in green ribbon and the amino acid residues involved in the H-bonding network are shown as yellow sticks and labeled black. MHC I binding pocket(s) are shown as electrostatic sphere. H-bonds are displayed as blue spheres and the H-bonding distances are labeled blue. H-bonding interaction between the amino acid residues of the epitope and those of the MHC I are detailed in additional file 10- Table S7


**Additional file 10-Table S7:** Hydrogen Bonds and binding statistics of control epitope 380-ELRSRYWAIRTRSG-393 from IvAgNP with MHC I complexes

Epitope-MHC I complex	No. of H-bonds	Binding energy (kcal/mol)	Receptor residues in MHC I	Ligand residues in epitope	Interacting atoms	H-bond distance (Å)
Epitope (380-ELRSRYWAI-388)-HLA-B8	10	-177.86	R62	E1	H-O	2.42
			R62	E1	H-O	1.74
			S77	I9	H-O	2.57
			T163	L2	H-O	2.13
			Y7	R3	O-H	2.45
			Y7	Y6	O-H	1.88
			Y59	R3	O-H	2.29
			N63	R3	O-H	2.22
			N114	W7	O-H	2.67
			Y171	R3	O-H	2.78
Epitope (381-LRSRYWAIR-389)-HLA-B27	14	-234.19	R62	Y5	H-O	2.25
			R62	W6	H-O	2.15
			R62	W6	H-O	2.36
			R62	Y5	H-O	1.82
			K70	R2	H-O	2.65
			Y84	L1	H-O	1.95
			T143	L1	H-O	2.38
			W147	L1	H-O	1.56
			Y159	A7	H-O	2.07
			Y171	R9	H-O	1.89
			E63	R9	O-H	2.75
			D77	R2	O-H	1.92
			Y99	R4	O-H	1.94
			Y99	R4	O-H	2.43


<sup>a</sup>Hydrogen bonding distance and binding energy were analyzed in Molsoft ICM-pro 3.5 computer program. Nine amino acids in each 9-mer epitope have been numbered 1-9.

**Additional file 11-Figure S4:** Docking of predicted strongest epitope 301-IDPFRLLLQNSQVYSL-315 from IvAgNP with HLA-A2 (A), A3 (B), B27 (C), B39 (D) and B58 (E)<sup>a</sup>


**A**




**B**




**C**



**D**



**E**





<sup>a</sup>MHC I structures are shown in grey ribbon and the amino acid residues involved in the H-bonding interaction are shown as red sticks and labeled red. The epitope is shown as in green ribbon and the amino acid residues involved in the H-bonding network are shown as yellow sticks and labeled black. MHC I binding pocket(s) are shown as electrostatic sphere. H-bonds are displayed as blue spheres and the H-bonding distances are labeled blue. H-bonding interaction between the amino acid residues of the epitope and those of the MHC I are detailed in additional file 12- Table S8

**Additional file 12-Table S8:** Hydrogen Bonds and binding statistics of predicted strongest epitope 301-IDPFRLQLNSQVYSL-315 from IvAgNP with MHC I complexes<sup>a</sup>

Epitope-MHC I complex	No. of H-bonds	Binding energy (kcal/mol)	Receptor residues in MHC I	Ligand residues in epitope	Interacting atoms	H-bond distance (Å)
Epitope (307-LQNSQVYSL-315)-HLA-A2	13	-195.63	Q72	S4	H-O	2.79
			Y116	L1	H-O	2.66
			W147	Q2	H-O	2.58
			Y159	S4	H-O	1.84
			Y159	S4	H-O	1.92
			R65	L9	O-H	2.70
			Y99	Y7	O-H	2.11
			Y159	S6	O-H	2.22
			G162	Y7	O-H	2.13
			Y84	N3	O-H	1.90
			R65	L9	O-H	2.35
			Y84	N3	H-O	2.40
			H70	Y7	H-O	3.00
Epitope (305-RLLQNSQVY-313)-HLA-A3	11	-204.35	Q62	R1	H-O	2.18
			Q72	N5	H-O	1.75
			Q72	N5	H-O	2.71
			Y159	L3	H-O	2.55
			E154	L3	H-O	1.49
			Y99	Q4	O-H	2.70
			A136	S6	O-H	1.80
			E89	Q7	H-O	1.68
			E89	Q7	H-O	1.91
			R108	V8	H-O	2.52
			Q155	V8	H-O	2.10
Epitope (304-FRLQNSQV-312)-HLA-B27	11	-199.62	E63	N5	H-O	2.61
			Y159	L4	H-O	2.07
			Q65	N5	H-O	1.95
			D77	V9	H-O	1.83
			T143	V9	H-O	2.01
			W147	Q8	H-O	2.50
			Y159	L4	H-O	2.35
			Y171	F1	H-O	2.14
			E63	L9	O-H	2.40
			D116	L3	O-H	1.88
			D116	L3	O-H	2.41
Epitope (307-LQNSQVYSL-315)-HLA-B39	10	-191.13	R111	L1	H-O	1.81
			N63	S4	H-O	2.51
			Y99	Y7	H-O	2.31
			Y99	S4	H-O	2.39
			Y159	Q2	H-O	1.72
			Q155	Q2	O-H	1.73
			Q65	Y7	O-H	1.90
			T73	Y7	O-H	2.61
			Y84	L9	O-H	2.52
			L78	L9	O-H	2.66
			T73	Y7	O-H	2.67
Epitope (305-RLLQNSQVY-313)-HLA-B58	9	-185.32	E154	R1	H-O	3.11
			R151	L2	H-O	2.61
			W147	L3	H-O	2.64
			R111	L2	H-O	1.82
			T143	N5	O-H	1.63
			K68	V8	O-H	2.24
			E63	N5	O-H	2.31
			Y59	N5	H-O	1.70
			E63	N5	H-O	1.61

<sup>a</sup>Hydrogen bonding distance and binding energy were analyzed in Molsoft ICM-pro 3.5 computer program. Nine amino acids in each 9-mer epitope have been numbered 1-9.

**Additional file 13-Figure S5: Multiple alignments of amino acid sequences of HLA-A and HLA-B series**

		59		84	
HLA-A02	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>	<u>Y</u>	<u>W</u>	TRKVKAHQSQTDRVDLGTLRGYYNQSE 89
HLA-A24	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>	<u>Y</u>	<u>W</u>	ETGKVKAHQSQTDRNLRIALRYYNQSE 89
HLA-A11	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDQETRNVKAQSQTDRVDLGTLRGYYNQSE 89
HLA-A25	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDRNTRNVKAHSQTDRESLRIALRYYNQSE 89
HLA-A36	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDQETRNMKAHSQTDRLNLTGLTRGYYNQSE 89
HLA-A33	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDRNTRNVKAHSQIDRVDLGTLRGYYNQSE 89
HLA-A32	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDQETRNVKAHSQTDRESLRIALRYYNQSE 89
HLA-A31	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDQETRNVKAHSQIDRVDLGTLRGYYNQSE 89
HLA-A30	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDQETRNVKAQSQTDRVDLGTLRGYYNQSE 89
HLA-A29	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDLQTRNVKAQSQTDRANLGTLRGYYNQSE 89
HLA-A74	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDQETRNVKAHSQTDRLVLTGLTRGYYNQSE 89
HLA-A68	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDRNTRNVKAQSQTDRVDLGTLRGYYNQSE 89
HLA-A01	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDQETRNMKAHSQTDRLNLTGLTRGYYNQSE 89
HLA-A03	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDQETRNVKAQSQTDRVDLGTLRGYYNQSE 89
HLA-A34	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDRNTRNVKAQSQTDRVDLGTLRGYYNQSE 89
HLA-A26	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASQRMEPRAPWIEQEGPHE</u>			WDRNTRNVKAHSQTDRLNLTGLTRGYYNQSE 89
HLA-B27	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPREPRAPWIEQEGPHE</u>	<u>Y</u>	<u>W</u>	NDRETIQICKAKAQTDREDLRLLRYYNQSE 89
HLA-B44	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRMAPRAPWIEQEGPHE</u>	<u>Y</u>	<u>W</u>	NDRETIQISKTNTQTYRENLRNLRYYNQSE 89
HLA-B78	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRTEPRAPWIEQEGPHE</u>			WDRNTQIFKTNTQTDRESLRNLRYYNQSE 89
HLA-B67	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPREPRAPWIEQEGPHE</u>			WDRNTQIYKAQAQTDRESLRNLRYYNQSE 89
HLA-B58	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRTEPRAPWIEQEGPHE</u>			WDGETRNMKASAQTYRENLRIALRYYNQSE 89
HLA-B57	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRTEPRAPWIEQEGPHE</u>			WDRNTQIFKTNTQTYRENLRIALRYYNQSE 89
HLA-B53	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRTEPRAPWIEQEGPHE</u>			WDRNTQIFKTNTQTYRENLRIALRYYNQSE 89
HLA-B52	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRTEPRAPWIEQEGPHE</u>			WDRETQISKTNTQTYRENLRIALRYYNQSE 89
HLA-B51	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRTEPRAPWIEQEGPHE</u>			WDRNTQIFKTNTQTYRENLRIALRYYNQSE 89
HLA-B46	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRMAPRAPWIEQEGPHE</u>			WDRETQYKQKRAQTDRLVLRNLRYYNQSE 89
HLA-B41	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRKEPRAPWIEQEGPHE</u>			WDRETQISKTNTQTYRESLRNLRYYNQSE 89
HLA-B38	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPREPRAPWIEQEGPHE</u>			WDRNTQICKTNTQTYRENLRIALRYYNQSE 89
HLA-B35	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRTEPRAPWIEQEGPHE</u>			WDRNTQIFKTNTQTYRESLRNLRYYNQSE 89
HLA-B18	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRMAPRAPWIEQEGPHE</u>			WDRNTQISKTNTQTYRESLRNLRYYNQSE 89
HLA-B15	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRMAPRAPWIEQEGPHE</u>			WDRETQISKTNTQTYRESLRNLRYYNQSE 89
HLA-B13	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRMAPRAPWIEQEGPHE</u>			WDRETQISKTNTQTYRENLRNLRYYNQSE 89
HLA-B39	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPREPRAPWIEQEGPHE</u>			WDRNTQICKTNTQTDRESLRNLRYYNQSE 89
HLA-B73	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRMAPRAPWIEQEGPHE</u>			WDRNTQICKAKAQTDRLVLRNLRYYNQSE 89
HLA-B08	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPREPRAPWIEQEGPHE</u>			WDRNTQIFKTNTQTDRESLRNLRYYNQSE 89
HLA-B07	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPREPRAPWIEQEGPHE</u>			WDRNTQIYKAQAQTDRESLRNLRYYNQSE 89
HLA-B40	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRKEPRAPWIEQEGPHE</u>			WDRETQISKTNTQTYRESLRNLRYYNQSE 89
HLA-B54	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRMAPRAPWIEQEGPHE</u>			WDRNTQIYKAQAQTDRESLRNLRYYNQSE 89
HLA-B55	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPREPRAPWIEQEGPHE</u>			WDRNTQIYKAQAQTDRESLRNLRYYNQSE 89
HLA-B56	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPREPRAPWIEQEGPHE</u>			WDRNTQIYKAQAQTDRESLRNLRYYNQSE 89
HLA-B15	GSHSMRYFFTSVSRPGRGEPRI	<u>AVGYVDDTQFVRFSDAASPRMAPRAPWIEQEGPHE</u>			WDRETQISKTNTQTYRESLRNLRYYNQSE 89

		99		143	147	155	159	
HLA-A02	AGSHTVQRMYGCDVGS	<u>DRFLRGYHQAYDGKDYIALKEDLRSWTAADMAAQITTKHK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	VAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-A24	AGSHTLQMMYGC	<u>DRFLRGYHQAYDGKDYIALKEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	VAEQLRAYLEGTCVGLRRYLENGKETL 179
HLA-A11	DGSHTIQIMYGCDV	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGRCVEWLRRYLENGKETL 179
HLA-A25	DGSHTIQIRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGRCVEWLRRYLENGKETL 179
HLA-A36	DGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-A33	AGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRHLENGKETL 179
HLA-A32	AGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-A31	AGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-A30	AGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-A29	AGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-A74	AGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-A68	AGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALKEDLRSWTAADMAAQITTKHK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	VAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-A01	DGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGRCVGLRRYLENGKETL 179
HLA-A03	AGSHTIQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLDGTCVEWLRRYLENGKETL 179
HLA-A34	DGSHTIQIRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-A26	DGSHTIQIRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGRCVEWLRRYLENGKETL 179
HLA-B27	AGSHTLQMMYGC	<u>DRFLRGYHQAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B44	AGSHIQIRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B78	AGSHTWQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRHLENGKETL 179
HLA-B67	AGSHTLQRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B58	AGSHIQIRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B57	AGSHIQIRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B53	AGSHIQIRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B52	AGSHTWQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRHLENGKETL 179
HLA-B51	AGSHTWQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRHLENGKETL 179
HLA-B46	AGSHTLQRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B41	AGSHTWQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B38	AGSHTLQRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B35	AGSHIQIRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B18	AGSHTLQRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRHLENGKETL 179
HLA-B15	AGSHTLQRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B13	AGSHIQIRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B39	AGSHTLQRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B73	DGSHTWQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRHLENGKETL 179
HLA-B08	AGSHTLQSMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B07	AGSHTLQSMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B40	AGSHTLQSMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B54	AGSHTWQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B55	AGSHTWQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B56	AGSHTWQIMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179
HLA-B15	AGSHTLQRMYGCD	<u>GRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITTKRK</u>	<u>W</u>	<u>Q</u>	<u>E</u>	<u>A</u>	<u>A</u>	HAEQLRAYLEGTCVEWLRRYLENGKETL 179

The HLA-A02 sequence is chosen as reference. Position 59 (Y), 94 (Y), 99 (Y), 142 (T), 147 (W), 155 (Q) and 159 (Y) are marked as boxes to present no polymorphic binding site in the MHC protein. All Binding residues are labeled red and underlined.